Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Nov;81(6):972–980. doi: 10.1038/sj.bjc.6690795

Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab́ fragments

J L Casey 1, R B Pedley 1, D J King 2,1, A J Green 1, G T Yarranton 2,1, R H J Begent 1
PMCID: PMC2362943  PMID: 10576653

Abstract

We have been investigating the use of cross-linked divalent (DFM) and trivalent (TFM) versions of the anti-carcinoembryonic antigen (CEA) monoclonal antibody A5B7 as possible alternatives to the parent forms (IgG and F(ab́)2) which have been used previously in clinical radioimmunotherapy (RIT) studies in colorectal carcinoma. Comparative biodistribution studies of similar sized DFM and F(ab́)2 and TFM and IgG, radiolabelled with both 131I and 90Y have been described previously using the human colorectal tumour LS174T nude mouse xenograft model (Casey et al (1996) Br J Cancer 74: 1397–1405). In this study quantitative estimates of radiation distribution and RIT in the xenograft model provided more insight into selecting the most suitable combination for future RIT. Radiation doses were significantly higher in all tissues when antibodies were labelled with 90Y. Major contributing organs were the kidneys, liver and spleen. The extremely high absorbed dose to the kidneys on injection of 90Y-labelled DFM and F(ab́)2 as a result of accumulation of the radiometal would result in extremely high toxicity. These combinations are clearly unsuitable for RIT. Cumulative dose of 90Y-TFM to the kidney was 3 times lower than the divalent forms but still twice as high as for 90Y-IgG. TFM clears faster from the blood than IgG, producing higher tumour to blood ratios. Therefore when considering only the tumour to blood ratios of the total absorbed dose, the data suggests that TFM would be the most suitable candidate. However, when corrected for equitoxic blood levels, doses to normal tissues for TFM were approximately twice the level of IgG, producing a two-fold increase in the overall tumour to normal tissue ratio. In addition RIT revealed that for a similar level of toxicity and half the administered activity, 90Y-IgG produced a greater therapeutic response. This suggests that the most promising A5B7 antibody form with the radionuclide 90Y may be IgG. Dosimetry analysis revealed that the tumour to normal tissue ratios were greater for all 131I-labelled antibodies. This suggests that 131I may be a more suitable radionuclide for RIT, in terms of lower toxicity to normal tissues. The highest tumour to blood dose and tumour to normal tissue ratio at equitoxic blood levels was 131I-labelled DFM, suggesting that 131I-DFM may be best combination of antibody and radionuclide for A5B7. The dosimetry estimates were in agreement with RIT results in that twice the activity of 131I-DFM must be administered to produce a similar therapeutic effect as 131I-TFM. The toxicity in this therapy experiment was minimal and further experiments at higher doses are required to observe if there would be any advantage of a higher initial dose rate for 131I-DFM. © 1999 Cancer Research Campaign

Keywords: dosimetry, radioimmunotherapy, tumour targeting, divalent Fab́, tri-valent Fab́

Full Text

The Full Text of this article is available as a PDF (171.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antoniw P., Farnsworth A. P., Turner A., Haines A. M., Mountain A., Mackintosh J., Shochat D., Humm J., Welt S., Old L. J. Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM). Br J Cancer. 1996 Aug;74(4):513–524. doi: 10.1038/bjc.1996.395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Behr T. M., Sharkey R. M., Juweid M. E., Blumenthal R. D., Dunn R. M., Griffiths G. L., Bair H. J., Wolf F. G., Becker W. S., Goldenberg D. M. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res. 1995 Sep 1;55(17):3825–3834. [PubMed] [Google Scholar]
  3. Casey J. L., King D. J., Chaplin L. C., Haines A. M., Pedley R. B., Mountain A., Yarranton G. T., Begent R. H. Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments. Br J Cancer. 1996 Nov;74(9):1397–1405. doi: 10.1038/bjc.1996.555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. DePalatis L. R., Frazier K. A., Cheng R. C., Kotite N. J. Lysine reduces renal accumulation of radioactivity associated with injection of the [177Lu]alpha-[2-(4-aminophenyl) ethyl]-1,4,7,10-tetraaza-cyclodecane-1,4,7,10-tetraacetic acid-CC49 Fab radioimmunoconjugate. Cancer Res. 1995 Nov 15;55(22):5288–5295. [PubMed] [Google Scholar]
  5. Durbin P. W., Jeung N., Kullgren B., Clemons G. K. Gross composition and plasma and extracellular water volumes of tissues of a reference mouse. Health Phys. 1992 Oct;63(4):427–442. doi: 10.1097/00004032-199210000-00007. [DOI] [PubMed] [Google Scholar]
  6. Fawwaz R. A., Wang T. S., Srivastava S. C., Hardy M. A. The use of radionuclides for tumor therapy. Int J Rad Appl Instrum B. 1986;13(4):429–436. doi: 10.1016/0883-2897(86)90021-8. [DOI] [PubMed] [Google Scholar]
  7. Fowler J. F. Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys. 1990 May;18(5):1261–1269. doi: 10.1016/0360-3016(90)90467-x. [DOI] [PubMed] [Google Scholar]
  8. Ghetie V., Popov S., Borvak J., Radu C., Matesoi D., Medesan C., Ober R. J., Ward E. S. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol. 1997 Jul;15(7):637–640. doi: 10.1038/nbt0797-637. [DOI] [PubMed] [Google Scholar]
  9. Harrison A., Walker C. A., Parker D., Jankowski K. J., Cox J. P., Craig A. S., Sansom J. M., Beeley N. R., Boyce R. A., Chaplin L. The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates. Int J Rad Appl Instrum B. 1991;18(5):469–476. doi: 10.1016/0883-2897(91)90107-v. [DOI] [PubMed] [Google Scholar]
  10. Johnston R. F., Pickett S. C., Barker D. L. Autoradiography using storage phosphor technology. Electrophoresis. 1990 May;11(5):355–360. doi: 10.1002/elps.1150110503. [DOI] [PubMed] [Google Scholar]
  11. King D. J., Antoniw P., Owens R. J., Adair J. R., Haines A. M., Farnsworth A. P., Finney H., Lawson A. D., Lyons A., Baker T. S. Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy. Br J Cancer. 1995 Dec;72(6):1364–1372. doi: 10.1038/bjc.1995.516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. King D. J., Turner A., Farnsworth A. P., Adair J. R., Owens R. J., Pedley R. B., Baldock D., Proudfoot K. A., Lawson A. D., Beeley N. R. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res. 1994 Dec 1;54(23):6176–6185. [PubMed] [Google Scholar]
  13. Kobayashi H., Le N., Kim I. S., Kim M. K., Pie J. E., Drumm D., Paik D. S., Waldmann T. A., Paik C. H., Carrasquillo J. A. The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points. Cancer Res. 1999 Jan 15;59(2):422–430. [PubMed] [Google Scholar]
  14. Kobayashi H., Yoo T. M., Kim I. S., Kim M. K., Le N., Webber K. O., Pastan I., Paik C. H., Eckelman W. C., Carrasquillo J. A. L-lysine effectively blocks renal uptake of 125I- or 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment. Cancer Res. 1996 Aug 15;56(16):3788–3795. [PubMed] [Google Scholar]
  15. Lane D. M., Eagle K. F., Begent R. H., Hope-Stone L. D., Green A. J., Casey J. L., Keep P. A., Kelly A. M., Ledermann J. A., Glaser M. G. Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies. Br J Cancer. 1994 Sep;70(3):521–525. doi: 10.1038/bjc.1994.338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Pedley R. B., Boden J. A., Boden R. W., Green A., Boxer G. M., Bagshawe K. D. The effect of serum CEA on the distribution and clearance of anti-CEA antibody in a pancreatic tumour xenograft model. Br J Cancer. 1989 Oct;60(4):549–554. doi: 10.1038/bjc.1989.311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Pedley R. B., Boden J. A., Boden R., Boxer G. M., Flynn A. A., Keep P. A., Begent R. H. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res. 1996 Jul 15;56(14):3293–3300. [PubMed] [Google Scholar]
  18. Pedley R. B., Boden J. A., Boden R., Dale R., Begent R. H. Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model. Br J Cancer. 1993 Jul;68(1):69–73. doi: 10.1038/bjc.1993.288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Press O. W., Shan D., Howell-Clark J., Eary J., Appelbaum F. R., Matthews D., King D. J., Haines A. M., Hamann P., Hinman L. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 1996 May 1;56(9):2123–2129. [PubMed] [Google Scholar]
  20. Schott M. E., Milenic D. E., Yokota T., Whitlow M., Wood J. F., Fordyce W. A., Cheng R. C., Schlom J. Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules. Cancer Res. 1992 Nov 15;52(22):6413–6417. [PubMed] [Google Scholar]
  21. Sharkey R. M., Motta-Hennessy C., Pawlyk D., Siegel J. A., Goldenberg D. M. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res. 1990 Apr 15;50(8):2330–2336. [PubMed] [Google Scholar]
  22. Sumpio B. E., Hayslett J. P. Renal handling of proteins in normal and disease states. Q J Med. 1985 Oct;57(222):611–635. [PubMed] [Google Scholar]
  23. Sung C., Shockley T. R., Morrison P. F., Dvorak H. F., Yarmush M. L., Dedrick R. L. Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors. Cancer Res. 1992 Jan 15;52(2):377–384. [PubMed] [Google Scholar]
  24. Tarburton J. P., Halpern S. E., Hagan P. L., Sudora E., Chen A., Fridman D. M., Pfaff A. E. Effect of acetylation on monoclonal antibody ZCE-025 Fab': distribution in normal and tumor-bearing mice. J Biol Response Mod. 1990 Apr;9(2):221–230. [PubMed] [Google Scholar]
  25. Yokota T., Milenic D. E., Whitlow M., Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 1992 Jun 15;52(12):3402–3408. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES